evidence varies by claim

Dulaglutide

Metabolic & Endocrine

Dulaglutide is indexed as peptide in the PeptideBase article library. It is referenced in “Do GLP-1 Drugs Increase Bowel Obstruction Risk? What a 298,124-Person Study Found” and 1 other PeptideBase article. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.

Research status: evidence varies by claim

Deep Dives on Dulaglutide

Start here for the plain-English articles connected to this peptide.

Research & Evidence9 min read

GLP-1 Drugs and Gastroparesis: What 13 Published Cases Can—and Cannot—Show

A 2026 systematic review found only 12 case reports describing 13 patients. Here is what that GLP-1 gastroparesis evidence signals—and why it cannot establish incidence, causality, or comparative drug risk.

Read article

metabolic10 min read

Do GLP-1 Drugs Increase Bowel Obstruction Risk? What a 298,124-Person Study Found

A nationwide Japanese study found no increased one-year risk of serious bowel obstruction or ileus after GLP-1 receptor-agonist initiation versus SGLT2-inhibitor initiation, but important limits remain.

Read article

Quick Facts

Origin: Named peptide referenced in PeptideBase coverage
Category: Metabolic & Endocrine

Research Areas